Our research
Our group at the department of Cell and Molecular Biology studies the genetic underpinnings of specific diseases; for example how genetic mutations translate into tubular structures forming incorrectly, compromise vascular integrity, or predispose to neural dysfunction. Within this, our lab has two main focuses:
- Notch signaling deregulation in Alagille syndrome, and Notch control of biliary and vascular development therein.
- Development of ultrasound-guided in utero nanoinjection as a powerful tool to manipulate gene expression in specific organs during development.
Alagille syndrome is a pediatric disorder caused by mutations in the ligand JAGGED1 or the receptor NOTCH2. Patients with this syndrome display paucity of bile ducts, heart defects, vertebral and ocular malformations and stereotypic facial features. We investigate the role of Notch signaling in bile duct development, liver regeneration and liver malignancy in a mouse model for Alagille syndrome and in human patient material using RNA sequencing of liver and biliary organoids, as described by Hans Clevers lab (with whom we collaborate). We also investigate the role of Notch signaling in the vasculature, since a large portion of Alagille patients in fact die from vascular accidents. In this part of the project, we examine the cell-autonomous and non-cell-autonomous roles of Jagged1 in the development of endothelial and vascular smooth muscle cells in the vascular system.
In order to rapidly manipulate gene expression in the developing embryo, to answer basic biological questions in various organ systems, we have collaborated with Elaine Fuchs’s group and further developed ultrasound-guided nanoinjection to target other organ systems than the skin. We use this technology to screen gene libraries for roles in cancer or normal development of various organ systems, with a focus on the nervous system.
